All In Biotech

Drug Trial Radar · NCT02559895

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Last checked: Nov 20, 2026Latest source record: May 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 898 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

898

Actual

Start

Sep 2015

Primary completion

Feb 2017

Study completion Dec 2017

Sponsor

Lead sponsor
Alder Biopharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.

Conditions

  • Migraine Disorders

Interventions

  • ALD403Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Monthly Migraine Days (Weeks 1-12)Time frame: Week 1-12

Locations

87 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    Long Beach, California

  • Research Site

    Montclair, California

  • Research Site

    Oceanside, California

  • Research Site

    Redlands, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Monica, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Fort Collins, Colorado

  • Research Site

    Stamford, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Bradenton, Florida

  • Research Site

    DeLand, Florida

  • Research site

    Fort Myers, Florida

  • Research Site

    Hallandale, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Maitland, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Sunrise, Florida

  • Research Site

    Winter Haven, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Lisle, Illinois

  • Research Site

    Prairie Village, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Owensboro, Kentucky

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.